JP2024530047A - ワクチン抗原 - Google Patents

ワクチン抗原 Download PDF

Info

Publication number
JP2024530047A
JP2024530047A JP2024508334A JP2024508334A JP2024530047A JP 2024530047 A JP2024530047 A JP 2024530047A JP 2024508334 A JP2024508334 A JP 2024508334A JP 2024508334 A JP2024508334 A JP 2024508334A JP 2024530047 A JP2024530047 A JP 2024530047A
Authority
JP
Japan
Prior art keywords
cov
vaccine
protein
antigen
trimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2024508334A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2023015352A5 (https=
JP2024530047A5 (https=
Inventor
ポウムボーリオス，パンテリス
ドラマー，ハイジ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Macfarlane Burnet Institute for Medical Research and Public Health Ltd
Original Assignee
Macfarlane Burnet Institute for Medical Research and Public Health Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2021902500A external-priority patent/AU2021902500A0/en
Application filed by Macfarlane Burnet Institute for Medical Research and Public Health Ltd filed Critical Macfarlane Burnet Institute for Medical Research and Public Health Ltd
Publication of JP2024530047A publication Critical patent/JP2024530047A/ja
Publication of JPWO2023015352A5 publication Critical patent/JPWO2023015352A5/ja
Publication of JP2024530047A5 publication Critical patent/JP2024530047A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20051—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2024508334A 2021-08-11 2022-08-11 ワクチン抗原 Withdrawn JP2024530047A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
AU2021902500A AU2021902500A0 (en) 2021-08-11 Vaccine Antigen
AU2021902500 2021-08-11
AU2021902530A AU2021902530A0 (en) 2021-08-13 Vaccine Antigen
AU2021902530 2021-08-13
PCT/AU2022/050429 WO2023015332A1 (en) 2021-08-11 2022-05-06 Vaccine antigen
AUPCT/AU2022/050429 2022-05-06
PCT/AU2022/050880 WO2023015352A1 (en) 2021-08-11 2022-08-11 Vaccine antigen

Publications (3)

Publication Number Publication Date
JP2024530047A true JP2024530047A (ja) 2024-08-14
JPWO2023015352A5 JPWO2023015352A5 (https=) 2025-08-15
JP2024530047A5 JP2024530047A5 (https=) 2025-08-15

Family

ID=85199645

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024508334A Withdrawn JP2024530047A (ja) 2021-08-11 2022-08-11 ワクチン抗原

Country Status (6)

Country Link
US (1) US20240350622A1 (https=)
EP (1) EP4384604A4 (https=)
JP (1) JP2024530047A (https=)
CN (1) CN118043451A (https=)
AU (1) AU2022326491A1 (https=)
WO (2) WO2023015332A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4604995A1 (en) 2022-10-17 2025-08-27 BioNTech SE Combination vaccines against coronavirus infection, influenza infection, and/or rsv infection
CN116726160B (zh) * 2023-08-09 2023-10-27 中国医学科学院医学生物学研究所 新冠病毒突变体通用型疫苗cRBD的制备与应用
WO2025035187A1 (en) * 2023-08-15 2025-02-20 Macfarlane Burnet Institute For Medical Research And Public Health Limited Vaccine antigen

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12194089B2 (en) * 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
MX2022009460A (es) * 2020-02-04 2022-12-16 Curevac Ag Vacuna contra el coronavirus.
MX2022015132A (es) * 2020-05-29 2023-03-08 CureVac SE Vacunas combinadas a base de acidos nucleicos.

Also Published As

Publication number Publication date
AU2022326491A1 (en) 2024-03-07
US20240350622A1 (en) 2024-10-24
EP4384604A4 (en) 2025-06-11
WO2023015352A1 (en) 2023-02-16
EP4384604A1 (en) 2024-06-19
WO2023015332A1 (en) 2023-02-16
CN118043451A (zh) 2024-05-14

Similar Documents

Publication Publication Date Title
US11964010B2 (en) Prefusion coronavirus spike proteins and their use
JP2026040566A (ja) ＳＡＲＳ－ＣｏＶ－２ワクチン
WO2021160346A1 (en) Nucleic acid vaccine against the sars-cov-2 coronavirus
JP7788403B2 (ja) 合成改変ワクシニアアンカラ（ｓＭＶＡ）ベースのコロナウイルスワクチン
US20240350622A1 (en) Vaccine Antigen
JP2016536346A (ja) 免疫原性の中東呼吸器症候群コロナウイルス（ＭＥＲＳ−ＣｏＶ）組成物および方法
US12403190B2 (en) Coronavirus vaccine and methods of use thereof
US11253587B2 (en) Vaccine compositions for the treatment of coronavirus
JP2023523423A (ja) ＳＡＲＳ－ＣｏＶ－２に対するワクチン及びその調製物
US11576960B2 (en) Respiratory syncytial virus (RSV) vaccines
ES2893542T3 (es) Vacuna
JP2024520730A (ja) コロナウイルスに対するウイルス様粒子ワクチン
JP2023529124A (ja) コロナウイルスワクチンコンストラクトおよびこれを作製し使用する方法
AU2023330867A1 (en) Vaccines against coronaviruses
US20240366753A1 (en) Viral-like particles for the treatment or prevention of an infection by a coronaviridae virus
AU2024324615A1 (en) Vaccine antigen
US20260083836A1 (en) Modified coronavirus spike antigen protein and uses thereof
US20220233682A1 (en) Vaccine compositions for the treatment of coronavirus
EP4541806A1 (en) Modified coronavirus spike antigen protein and uses thereof
EP4531903A1 (en) Vaccine with reduced anti-vector antigenicity
WO2026030724A1 (en) Sars-cov-2 vaccine
KR20250153796A (ko) 다중시스트론 백신 및 이의 제조 방법 및 사용 방법
WO2025017202A2 (en) Porphyromonas gingivalis antigenic constructs
IL282190A (en) Vaccine for sars-cov-2

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250806

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250806

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20251127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20251127